Rimonabant - Wikipedia

Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug that was first approved in Europe in 2006 but was withdrawn ...

Acomplia: Uses, Dosage, Side Effects & Warnings - Drugs.com

Sanofi-Aventis has withdrawn rimonabant from the market globally and it is no longer under development. 1 Acomplia was officially withdrawn by the European Medicines ...

Rimonabant - an overview | ScienceDirect Topics

Atrial fibrillation has been attributed to rimonabant in two cases [114 A]. • A man who took rimonabant for 5 weeks developed palpitation, fatigue, and exertional ...

Rimonabant | C22H21Cl3N4O - PubChem - The PubChem Project

Rimonabant is a pyrazole and piperidine derivative that acts as a selective cannabinoid type-1 receptor (CB1 RECEPTOR) antagonist. It inhibits the proliferation and ...

European Medicines Agency - - Acomplia

European Union agency responsible for the protection of public and animal health through the scientific evaluation and supervision of medicines.

Acomplia (Rimonabant) - Investigational Agent for the ...

Developed by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity. It works...Read More...

Rimonabant — Wikipédia

Le rimonabant (ou SR141716) est un médicament anorexigène contre l'obésité agissant comme un agoniste inverse des récepteurs cannabinoïdes CB1.

Rimonabant - Wikipedia, la enciclopedia libre

Rimonabant (conocido también como SR141716), [n 1] es un inhibidor del apetito que actualmente se encuentra fuera del mercado en gran parte del mundo.

Rimonabant – Wikipedia

Rimonabant ist ein Arzneistoff, der als Appetitzügler zur Behandlung des Übergewichts eingesetzt wurde, eigentlich allerdings zur Raucherentwöhnung von dem ...

The psychiatric side-effects of rimonabant.

RESULTS: Clinical trials have revealed that rimonabant may promote weight loss in obese patients, although it may also induce symptoms of anxiety and depression.